Melody Matej
Family · Mesquite, TXNPI 1093292096
Payments from drug & device makers
Across 341 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$820
- Axsome Therapeutics, Inc.$795
- AbbVie$721
- Amgen$630
- Lilly USA, LLC$573
- Abbott$568
- plus $4K from 35 others
What the payments were for
- Food & beverage$8,23998%
- Education$1632%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $820 |
| Axsome Therapeutics, Inc. | 15 | $795 |
| AbbVie | 52 | $721 |
| Amgen | 29 | $630 |
| Lilly USA, LLC | 48 | $573 |
| Abbott | 14 | $568 |
| Astellas Pharma US Inc | 15 | $562 |
| Novo Nordisk | 16 | $320 |
| Exact Sciences | 17 | $315 |
| Idorsia Pharmaceuticals US Inc | 14 | $280 |
| Pfizer | 15 | $265 |
| GSK | 19 | $234 |
| Sanofi | 2 | $200 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $160 |
| Medtronic | 3 | $156 |
| Kyowa Kirin, Inc. | 1 | $140 |
| Kowa Pharmaceuticals America, Inc. | 4 | $138 |
| Sanofi-aventis U.S. LLC | 3 | $133 |
| Johnson & Johnson | 7 | $132 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $130 |
| Cardiovascular Systems Inc. | 1 | $126 |
| Corcept Therapeutics | 4 | $120 |
| Grifols USA, LLC | 1 | $116 |
| Sumitomo Pharma America, Inc. | 1 | $105 |
| Exeltis, USA Inc. | 1 | $103 |
| Merck | 6 | $99 |
| Optinose US, Inc. | 1 | $82 |
| Boston Scientific | 2 | $49 |
| Boehringer Ingelheim | 2 | $49 |
| Dexcom, Inc. | 2 | $45 |
| Renalytix AI, Inc. | 2 | $39 |
| Cranial Technologies, Inc | 2 | $38 |
| Bayer | 2 | $33 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Cipher Pharmaceuticals US LLC | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Stryker | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$458
- Veozah$241
- AIRSUPRA$228
- FreeStyle Libre$144
- Diamondback Peripheral$126
- Micra$121
- FREESTYLE LIBRE 3$121
- Otezla$119
- QUVIVIQ$118
- Prolastin-C Liquid$116
- GEMTESA$105
- KRYSTEXXA$104
- VRAYLAR$104
- Twirla$103
- Slynd$103
- ZAVZPRET$102
How this compares
$8,402 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 39 | $43,084 |
| FarxigaDapagliflozin Propanediol | 37 | $40,580 |
| OzempicSemaglutide | 22 | $24,173 |
| WegovySemaglutide | 11 | $14,396 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,018 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,527 |
| Ventolin HfaAlbuterol Sulfate | 22 | $1,216 |
| Levothyroxine Sodium | 113 | $1,011 |
| Montelukast Sodium | 85 | $946 |
| Atorvastatin Calcium | 143 | $918 |
| Gabapentin | 55 | $914 |
| Doxycycline Monohydrate | 85 | $840 |
| Rosuvastatin Calcium | 61 | $789 |
| Omeprazole | 34 | $777 |
| Duloxetine Hcl | 32 | $773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $573 | $43,08439 claims |
| AstraZenecaFarxiga | $820 | $40,58037 claims |
| Novo NordiskOzempic, Wegovy | $320 | $38,57033 claims |
| GSKTrelegy Ellipta | $234 | $10,01811 claims |
| AbbVieSynthroid | $721 | $55412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Mesquite
- Corina SturgeonMesquite$38K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.